Research programme: cell and gene therapies - Baylor College of Medicine/Cell Medica

Drug Profile

Research programme: cell and gene therapies - Baylor College of Medicine/Cell Medica

Alternative Names: CAR-modified NKT cell therapy; Off-the-shelf allogeneic cell therapy; Off-the-shelf allogeneic NKT; T-cell receptor therapy - Cell Medica/Baylor College of Medicine

Latest Information Update: 01 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baylor College of Medicine
  • Developer Baylor College of Medicine; Cell Medica
  • Class Gene therapies; NKT cell therapies
  • Mechanism of Action Gene transference; Immunostimulants; Natural killer cell receptor modulators; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Solid tumours

Most Recent Events

  • 24 Aug 2016 Cell Medica in-licenses T Cell receptor technology from University College London
  • 17 Jun 2016 Cell Medica and Baylor College of Medicine enter into an exclusive licensing agreement and co-development agreement for cell and gene therapies for cancer
  • 17 Jun 2016 Baylor college of Medicine has patent protection for genetically engineered natural killer T-cells
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top